Compare TVRD & FOFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TVRD | FOFO |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | Hong Kong |
| Employees | 12 | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 29.7M |
| IPO Year | N/A | N/A |
| Metric | TVRD | FOFO |
|---|---|---|
| Price | $2.84 | $3.95 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $29.50 | N/A |
| AVG Volume (30 Days) | 45.6K | ★ 444.9K |
| Earning Date | 05-14-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $1.75 |
| 52 Week High | $43.65 | $68.00 |
| Indicator | TVRD | FOFO |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 54.76 |
| Support Level | N/A | $2.32 |
| Resistance Level | $4.32 | $5.96 |
| Average True Range (ATR) | 0.29 | 1.01 |
| MACD | -0.10 | 0.42 |
| Stochastic Oscillator | 2.34 | 32.84 |
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.